Literature DB >> 15011246

Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.

Xiaojuan Li1, Hua Jin, Ying Lu, Joonmi Oh, Susan Chang, Sarah J Nelson.   

Abstract

Although MR imaging (MRI) and MR spectroscopic imaging (MRSI) have been applied in the diagnosis and treatment planning for brain tumors, their prognostic significance has not yet been determined. The goal of this study was to identify pre-treatment MRI and MRSI parameters for patients with malignant glioma that may be useful in predicting survival. Two populations of patients with newly-diagnosed malignant glioma were examined with MRI and three-dimensional proton ((1)H) MRSI. Thirty-nine patients (22 grade 3 and 17 glioblastoma multiforme, GBM) were studied prior to surgery, and 33 GBM patients were studied after surgery but prior to treatment with radiation and chemotherapy. Signal intensities of choline (Cho), creatine (Cr), N-acetyl aspartate (NAA), and lactate/lipid (LL) were estimated from the spectra. Recursive partitioning methods were applied to parameters that included age, histological grade, MRI and MRSI variables to generate survival trees. Patients were grouped into high and low risk categories and the corresponding Kaplan-Meier curves were plotted for comparison between groups. The parameters that were selected by recursive partitioning as being predictive of poor outcome were older age, larger contrast enhancement, higher Cho-to-Cr, higher Cho-to-NAA, higher LL and lower Cr-to-NAA abnormalities. The survival functions were significantly different between the sub-groups of patients obtained from the survival tree for both pre-surgery and post-surgery data. The results of this study suggest that pre-treatment MRI and three-dimensional (1)H-MRSI provide information that predicts outcome for patients with malignant gliomas and have drawn attention to variables that should be examined prospectively in future studies using these techniques. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011246     DOI: 10.1002/nbm.858

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  33 in total

Review 1.  Clinical applications of imaging biomarkers. Part 3. The neuro-oncologist's perspective.

Authors:  A Shenoy
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Early prediction of response to Vorinostat in an orthotopic rat glioma model.

Authors:  Li Wei; Samuel Hong; Younghyoun Yoon; Scott N Hwang; Jaekeun C Park; Zhaobin Zhang; Jeffrey J Olson; Xiaoping P Hu; Hyunsuk Shim
Journal:  NMR Biomed       Date:  2012-02-02       Impact factor: 4.044

3.  Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.

Authors:  C Majós; J Bruna; M Julià-Sapé; M Cos; A Camins; M Gil; J J Acebes; C Aguilera; C Arús
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

4.  Quantitative temporal lobe differences: autism distinguished from controls using classification and regression tree analysis.

Authors:  E Shannon Neeley; Erin D Bigler; Lori Krasny; Sally Ozonoff; William McMahon; Janet E Lainhart
Journal:  Brain Dev       Date:  2007-01-03       Impact factor: 1.961

Review 5.  Image-based biomarkers in clinical practice.

Authors:  John E Bayouth; Thomas L Casavant; Michael M Graham; Milan Sonka; Manickam Muruganandham; John M Buatti
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 6.  MR-guided radiation therapy: transformative technology and its role in the central nervous system.

Authors:  Yue Cao; Chia-Lin Tseng; James M Balter; Feifei Teng; Hemant A Parmar; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

7.  Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.

Authors:  Kai Zhang; Chuanfu Li; Ying Liu; Li Li; Xiangxing Ma; Xiangshui Meng; Dechao Feng
Journal:  Neuroradiology       Date:  2007-09-01       Impact factor: 2.804

8.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

9.  Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.

Authors:  Manal Nicolasjilwan; Ying Hu; Chunhua Yan; Daoud Meerzaman; Chad A Holder; David Gutman; Rajan Jain; Rivka Colen; Daniel L Rubin; Pascal O Zinn; Scott N Hwang; Prashant Raghavan; Dima A Hammoud; Lisa M Scarpace; Tom Mikkelsen; James Chen; Olivier Gevaert; Kenneth Buetow; John Freymann; Justin Kirby; Adam E Flanders; Max Wintermark
Journal:  J Neuroradiol       Date:  2014-07-02       Impact factor: 3.447

10.  Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.

Authors:  Susan M Chang; Sarah Nelson; Scott Vandenberg; Soonmee Cha; Michael Prados; Nicholas Butowski; Michael McDermott; Andrew T Parsa; Manish Aghi; Jennifer Clarke; Mitchel Berger
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.